financetom
Business
financetom
/
Business
/
RBI gives big relief to Bandhan Bank, allows to open new branches
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
RBI gives big relief to Bandhan Bank, allows to open new branches
Feb 26, 2020 12:04 AM

Bandhan Bank received big relief from the Reserve Bank of India because the restriction on branch expansion would be very stifling for a young bank. Of course, Bandhan Bank got around it by taking over Gruh Finance.

The way RBI's letter is worded is interesting. The RBI said that although you are still violating the promoter dilution norms, since you have made an effort of going from 80 to 60, we think you will comply and therefore we are removing the restriction.

The Bandhan Bank promoter, which is the holding company, has to bring its stake down to 40 percent. It has brought its stake down to 60 percent from 80 percent because it issued extra shares when it acquired Gruh Finance.

This is a big deal for Bandhan Bank itself and we should see the share improve. One reason could be also that Kotak Mahindra Bank has also got a sop from RBI, they have been told that they can bring down their stake from 30 to 26 and remain there till there is dilution.

The original rule wanted Uday Kotak to bring its stake down to 20 percent – that’s not been done. So since they got a concession these people have got not that bigger concession. These guys have to bring down their stake but at least the punishment of not opening branches has gone away.

There is probably a side advantage, completely unconnected advantage – if RBI is in such a forgiving mood then there will be market participants who will think that maybe Axis Bank will get permission to own an insurance company a little more easily.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CVS Health Raises 2025 Guidance; Issues 2026 Guidance
CVS Health Raises 2025 Guidance; Issues 2026 Guidance
Mar 10, 2026
07:06 AM EST, 12/09/2025 (MT Newswires) -- CVS Health ( CVS ) said Tuesday it has raised its 2025 adjusted EPS guidance to a range of $6.60 to $6.70, from $6.55 to $6.65. Analysts polled by FactSet expect $6.62. The company also raised its revenue guidance for the year ending Dec. 31, 2025 to at least $400.0 billion, up from...
Trafigura lifts dividend payments in 2025 despite lower net profits
Trafigura lifts dividend payments in 2025 despite lower net profits
Mar 10, 2026
LONDON, Dec 9 (Reuters) - Global commodities trading house Trafigura raised its dividends by 50% to almost $3 billion in 2025, despite a small drop in net profits after a second consecutive year of recording high impairments. Trafigura's net profit fell 3% to $2.67 billion in its 2025 financial year, which ended on September 30, group results showed on Tuesday,...
Rio2 to Acquire Southern Peaks Mining's Majority Stake in Condestable Mine for US$217 Million
Rio2 to Acquire Southern Peaks Mining's Majority Stake in Condestable Mine for US$217 Million
Mar 10, 2026
07:13 AM EST, 12/09/2025 (MT Newswires) -- Rio2 ( RIOFF ) on Monday said it has agreed to acquire Southern Peaks Mining's 99.1% interest in the Condestable mine in Peru, positioning Rio2 ( RIOFF ) as a diversified Latin American gold miner with copper exposure. The deal consideration totals US$217 million, implying a transaction enterprise value of about $241 million,...
Pfizer partners with YaoPharma to develop weight management drug
Pfizer partners with YaoPharma to develop weight management drug
Mar 10, 2026
Dec 9 (Reuters) - Pfizer ( PFE ) said on Tuesday it entered into an exclusive licensing agreement with YaoPharma, a subsidiary of China's Shanghai Fosun Pharmaceutical, to develop and commercialize an experimental weight-management treatment. The therapy YP05002 is part of the GLP-1 agonist class of drugs and is currently in early-stage development. Under the terms of the agreement, YaoPharma...
Copyright 2023-2026 - www.financetom.com All Rights Reserved